Nihon Kohden (OTCMKTS:NHNKY) Lowered to “Hold” Rating by UBS Group

Nihon Kohden (OTCMKTS:NHNKY) was downgraded by research analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, Zacks Research upgraded Nihon Kohden to a “hold” rating in a research note on Monday, April 27th. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Nihon Kohden currently has an average rating of “Hold”.

Nihon Kohden Stock Performance

NHNKY stock opened at $9.23 on Wednesday. The firm has a market cap of $1.55 billion, a PE ratio of 16.77 and a beta of 0.37. The firm’s fifty day moving average is $9.17 and its 200 day moving average is $9.68. Nihon Kohden has a one year low of $8.12 and a one year high of $14.21.

Nihon Kohden (OTCMKTS:NHNKY) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.09). Nihon Kohden had a return on equity of 9.08% and a net margin of 5.90%.The firm had revenue of $297.47 million during the quarter, compared to analyst estimates of $299.98 million. Research analysts predict that Nihon Kohden will post 0.6 earnings per share for the current fiscal year.

About Nihon Kohden

Nihon Kohden Corporation is a Tokyo-based manufacturer of medical electronic equipment, founded in 1951. The company has built a reputation for innovation in patient monitoring and diagnostic systems, developing one of Japan’s earliest electrocardiogram (ECG) machines and pioneering transistor-based oscilloscopes for clinical use. Over the decades, Nihon Kohden has expanded its product portfolio to address a wide range of healthcare needs, from emergency response to intensive care and neurology.

The company’s core offerings include patient monitors, ECG and electroencephalograph (EEG) devices, defibrillators, infusion pumps, and neuromonitoring systems.